Search

Displaying results 91 - 100 of 145826 in total
  1. Drug

    Atacicept

    go.drugbank.com/drugs/DB06399
    ApprovedInvestigational

    Atacicept is a recombinant fusion glycoprotein that joins the ligand-binding portion of the human TACI receptor to a modified IgG1 Fc domain, allowing it to bind and neutralize two cytokines: B cell activating … factor (BAFF) and A Proliferation Inducing Ligand (APRIL).

    Categories: Amino Acids, Peptides, and ProteinsSynonyms: Human Transmembrane Activator and CAML Interactor (TACI) Immunoglobulin G1 Fc Domain Fusion Protein (Fc5)
  2. Drug

    CYP-001

    go.drugbank.com/drugs/DB15739
    Investigational

    These cells are then able to differentiate into bone, cartilage, and adipose tissue. The MCA-derived MSCs can be obtained from induced pluripotent stem cells (iPSCs) and then expanded in media. … These cells are used to treat chronic allergic airway disease and fibrosis, among other pathologies.

    Synonyms: Mesenchymoangioblast-derived mesenchymal stem cells
  3. Drug

    Zenocutuzumab

    go.drugbank.com/drugs/DB15559
    ApprovedInvestigational

    [A264833] On December 4, 2024, the FDA granted accelerated approval to zenocutuzumab for the treatment of non-small cell lung cancer and pancreatic adenocarcinoma. … [L51963] It works to attenuate aberrant cancer cell growth caused by genomic rearrangements involving the neuregulin 1 gene (NRG1), which is an oncogenic driver.

    Categories: Amino Acids, Peptides, and ProteinsSynonyms: Mcla-128 (igg1 bispecific antibody with enhanced antibody-dependent cell-mediated cytotoxicity (adcc) activity targeting her2 and her3 receptors.), Immunoglobulin g1, bispecific, anti-(human epidermal growth factor receptors, her2 and her3) (humanized clone mcla-128 .gamma.1-chain), disulfide with humanized clone mcla-128 light chain, dimer
  4. Drug

    Angelica archangelica root

    go.drugbank.com/drugs/DB14283
    Approved

    It is not an approved drug.

    Synonyms: Archangelica Officinalis Root Extract
  5. Drug

    Autologous Non-Hematopoietic Peripheral Blood Stem Cells

    go.drugbank.com/drugs/DB15867
    Investigational

    The cells have the characterizations of CD90+, CD133+, Oct-4+, CD45-, and CD71-.[L16363] … Autologous non-hematopoietic peripheral blood stem cells have been created into a formulation for use in a clinical trial (NCT04473170) by the Abu Dhabi Stem Cells Center.

  6. Drug

    NVD-001

    go.drugbank.com/drugs/DB18459
    Investigational

    Synonyms: Autologous osteogenic stem cells
  7. Drug

    Skin-derived ABCB5-positive Mesenchymal Stem cells

    go.drugbank.com/drugs/DB17862
    Investigational

    Skin-derived ABCB5-positive Mesenchymal Stem cells are under investigation in clinical trial NCT04971161 (Allogeneic Abcb5-positive Dermal Mesenchymal Stromal Cells for Treatment of CVU (Phase Iib)).

    Synonyms: Skin-derived ABCB5+ Mesenchymal Stem cells, Skin-derived ABCB5-positive Mesenchymal Stem cells
  8. Drug

    Human Embryonic Stem Cell-derived M Cell

    go.drugbank.com/drugs/DB15734
    Investigational

    These IMRCs are differentiated from human embryonic stem cells that are expanded and then harvested. … IMRCs are similar to MSCs in terms of their capacity for self-renewal and tri-lineage differentiation.

    Synonyms: immunity- and matrix-regulatory cells, Immunity-and-matrix-regulatory cells
  9. Drug

    Obecabtagene autoleucel

    go.drugbank.com/drugs/DB17362
    ApprovedInvestigational

    [L52450] Obecabtagene autoleucel was also investigated in other hematological cancers and systemic lupus erythematosus.[A265045] … Obecabtagene autoleucel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy with a fast off-rate binding profile for CD19.

    Categories: Antineoplastic cell and gene therapy, Antineoplastic and Immunomodulating AgentsSynonyms: PACKAGING SIGNAL (.PSI.), THE REV RESPONSIVE ELEMENT (RRE) AND THE CENTRAL POLYPURINE TRACT (CPPT) ARE RETAIN, SELF-INACTIVATING LENTIVIRAL VECTOR CONSISTING OF 5' FUSION BETWEEN THE CMV PROMOTER AND HIV LTR, WHERE THE CMV PROMOTER REPLACES THE U3 REGION.
  10. Drug

    Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells

    go.drugbank.com/drugs/DB15740
    Investigational

    Human olfactory mucosa-derived mesenchymal stem cells (OM-MSCs) reside in an accessible location of the nasal cavity and have properties of multipotency and high proliferation, which contributes to high … Currently, OM-MSCs does not have wide application as there is not yet a standard and unambiguous protocol for OM-MSC collection, isolation, and therapeutic application.

    Synonyms: Olfactory mucosa mesenchymal stem cells, Olfactory mucosa mesenchymal stem/stromal cells